Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 0.97 |
| ▸ | PGR | P06401 | 7/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | IL5 | P05113 | 1/20 | 0.97 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.97 |
| ▸ | AR | P10275 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | MMP9 | P14780 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL9763339 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17168987 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL16139563 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024037644-A1 | PEG-MODIFIED GLUCOCORTICOID MEDICAMENT AND USE THEREOF | 津药生物科技（天津）有限公司 | 2024-02-22 | — | — | WO | disclosed |
| US-8710036-B2 | Carbonate and carbamate modified forms of glucocorticoids in combination with β2 adrenergic agonists | SUNOVION PHARMACEUTICALS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130244988-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8445470-B2 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SUNOVION PHARMACEUTICALS INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20090163456-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | SEPRACOR INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7468362-B2 | Carbonate and carbamate modified forms of glucocorticoids in combination with β2 adrenergic agonists | SEPRACOR INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080103119-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | SEPRACOR INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7253156-B2 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SEPRACOR INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060148775-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SEPRACOR INC. (US) | 2006-07-06 | — | — | US | disclosed |
| US-7018995-B2 | Carbonate and carbamate modified forms of glucocorticoids | SEPRACOR INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050009798-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SEPRACOR INC. (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004047845-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH β2 ADRENERGIC AGONISTS | SEPRACOR INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030176407-A1 | Carbonate and carbamate modified forms of glucocorticoids | SEPRACOR INC. (US) | 2003-09-18 | — | — | US | disclosed |
| WO-2003070745-A2 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS | SEPRACOR INC. (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148775-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | ADRB2, ADRA2C, NR3C2 | NR3C1 12/4885PGR 449/4885CYP3A4 698/4885 |
| US-20080103119-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | ADRB2, ADRA2C, NR3C2 | NR3C1 12/4885PGR 449/4885CYP3A4 698/4885 |
| US-20130244988-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | ADRB2, CHRM2, NR3C2 | NR3C1 10/4885PGR 443/4885CYP3A4 698/4885 |
| US-20090163456-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | ADRB2, CHRM2, NR3C2 | NR3C1 10/4885PGR 443/4885CYP3A4 698/4885 |
| US-20030176407-A1 | Carbonate and carbamate modified forms of glucocorticoids | NR3C1, NR5A1, NR3C2 | NR3C1 1/4885PGR 753/4885CYP3A4 440/4885 |
| US-20050009798-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | ADRB2, ADRA2C, NR3C2 | NR3C1 12/4885PGR 449/4885CYP3A4 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.